Table 7.

Phase 1b GO30140 study (arm F): objective response [modified from 37]

	IRF RECIST v1.1
	Atezo + Beva (n = 60)	Atezo (n = 59)
Confirmed ORR	12 (20%) (11–32)	10 (17%) (8–29)
CR	1 (2%)	3 (5%)
PR	11 (18%)	7 (12%)
SD	28 (47%)	19 (32%)
Non-CR/non-PD	0	1 (2%)
PD	17 (28%)	25 (42%)
DCR	40 (67%)	29 (49%)
Median DOR, months	NE (NE)	NE (3.7 to NE)

Median duration of follow-up: 6.6 months. Figures are presented as n (%) or n (%) (95% CI). IRF, independent review facility; Atezo, atezolizumab; Beva, bevacizumab; ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; DOR, duration of response; NE, not estimable.